Christie M. Ballantyne, MD Professor of Medicine and Director, Center for Cardiovascular Disease Prevention, Houston Methodist DeBakey Heart and Vascular Center, Baylor College of Medicine, Houston, Texas
Harold E. Bays, MD Medical Director, Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky
Peter H. Jones, MD Associate Professor of Medicine, Houston Methodist DeBakey Heart and Vascular Center, Baylor College of Medicine, Houston, Texas
Currently, 31% of the population in the United States have triglyceride (TG) levels >150 mg/dL. Except for the long-established relation between very high TGs and pancreatitis, the clinical significance of hypertriglyceridemia is still unclear. Whether elevated TGs are a direct cause or only a marker for atherosclerosis has been a topic of debate for many years. This question and other issues, including evaluation and best treatment of patients with elevated TGs, are addressed in this Editor's Roundtable. READ MORE »
Vincent E. Friedewald, Christie M. Ballantyne, Harold E. Bays, Peter H. Jones
Residual cardiovascular (CV) risk remains in dyslipidemic patients despite intensive statin therapy, underscoring the need for additional intervention. READ MORE »
Borow KM, Nelson JR, Mason RP
After the introduction of statins, clinical emphasis first focused on LDL cholesterol-lowering, then on the potential for raising HDL cholesterol, with less focus on lowering triglycerides. However, the understanding from genetic studies and negative results ... READ MORE »
Nordestgaard BG, Varbo A
AMR101 is an omega-3 fatty acid agent containing >96% pure icosapent-ethyl, the ethyl ester of eicosapentaenoic acid. The efficacy and safety of AMR101 were evaluated in this phase 3, multicenter, placebo-controlled ... READ MORE »
Ballantyne CM, Bays HE, Kastelein JJ, et al
Icosapent ethyl (IPE; formerly AMR101) is a high-purity prescription form of eicosapentaenoic acid ethyl ester. In the MARINE study we evaluated the efficacy and safety of IPE in patients with very high triglycerides ... READ MORE »
Bays HE, Braeckman RA, Ballantyne CM, et al
AMR101 is an omega-3 fatty acid agent containing >96% eicosapentaenoic acid ethyl ester and no docosahexaenoic acid. Previous smaller studies suggested that highly purified eicosapentaenoic acid lowered triglyceride ... READ MORE »
Bays HE, Ballantyne CM, Kastelein JJ, et al
Plasma triglyceride concentration is a biomarker for circulating triglyceride-rich lipoproteins and their metabolic remnants. Common mild-to-moderate hypertriglyceridaemia is typically multigenic, and results from the ... READ MORE »
Hegele RA, Ginsberg HN, Chapman MJ, on behalf of the European Atherosclerosis Society Consensus Panel
This study aimed to assess the balance of serum n-3 to n-6 polyunsaturated fatty acids (PUFAs) in patients with acute coronary syndrome (ACS). We enrolled 1,119 patients who were treated and in whom serum PUFA ... READ MORE »
Nishizaki Y, Shimada K, Tani S, et al
This review focuses on remnant cholesterol as a causal risk factor for ischemic heart disease (IHD), on its definition, measurement, atherogenicity, and levels in high risk patient groups; in addition, present and ... READ MORE »
Varbo A, Benn M, Nordestgaard BG
Eicosapentaenoic acid (EPA) is one of the n-3 polyunsaturated fatty acids (PUFA) found large quantities in fish oil. Ever since Dyerberg and Bang reported that EPA levels were high in the blood and diets of Greenland Inuit (who have low prevalence of atherosclerotic diseases), the preventive effects of n-3 PUFA, including EPA, has been examined in many epidemiological and clinical studies... READ MORE »
Yasushi Saito, Mitsuhiro Yokoyama, Hideki Origasa, et al
N Engle J Med. 2014:371:22-31.
N Engl J Med. 2014;371:32-41.
Nature. 2014. [Epub ahead of print]
Am J Cardiovasc Drugs. 2013;13:37-46.
Nat Genet. 2013;45:1345-1352.
Exp Rev Cardiovasc Drugs. 2012;10:687-695.
Made possible through an educational grant provided by Amarin.
Click question to view video responseWhat is the relationship between triglycerides and other lipids? How do triglycerides relate to insulin resistance? How do triglycerides relate to pancreatitis? Do elevated triglycerides cause symptoms? How do you evaluate the patient with elevated triglycerides? What organs are directly affected by elevated triglycerides? How do triglycerides relate to inflammation? How do triglycerides relate to adipose tissue? Are triglycerides atherogenic? How should triglycerides be measured in the clinical setting? How much do triglyceride levels vary during the day? Does recent food intake affect the triglyceride level? What lifestyle recommendations do you make for the patient with elevated triglycerides? What is the role of fibrates, niacin, and statins in treating elevated triglycerides? How do you treat diabetic patients with elevated triglycerides? What is the role of exercise in treating elevated triglycerides? Why do we need a new drug for treating elevated triglycerides? What is the rationale for EPA? What did the MARINE and ANCHOR trials tell us? How do you use EPA in your practice? Do you envision a greater emphasis on triglycerides now that EPA is available? Is EPA a "natural" treatment? At what triglyceride level is EPA indicated?
CME Released: 12/20/2013
Valid for credit through 12/20/2014
CME Released: 07/30/2013
Valid for credit through 07/30/2014
Posting Dates: 8/20/13 – 8/19/14
Posting Dates: 12/31/13 – 12/31/14
Posting Dates: 7/10/13 – 6/17/15